13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters

      research-article
      1 , 2 , 3 , , 4 , 5 , 6 , 7 , 8 , 9 , 5 , 8 , 10 , 11 , 12 , 13 , 10 , 14 , 3 , 15 , 14 , 3 , 16 , 6 , 4 , 17 , 19 , 1 , 9 , 17 , 18 , 2 , 20 , 21 , 16 , 10 , 1 , 2
      International Journal of Bipolar Disorders
      Springer Berlin Heidelberg
      Blood urea nitrogen, Body-mass index, Creatinine, eGFR, Glomerular filtration rate, Glucose, Lithium, Staging of renal function, White blood cell count

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Concerns about potential adverse effects of long-term exposure to lithium as a mood-stabilizing treatment notably include altered renal function. However, the incidence of severe renal dysfunction; rate of decline over time; effects of lithium dose, serum concentration, and duration of treatment; relative effects of lithium exposure vs. aging; and contributions of sex and other factors all remain unclear.

          Methods

          Accordingly, we acquired data from 12 collaborating international sites and 312 bipolar disorder patients (6142 person-years, 2669 assays) treated with lithium carbonate for 8–48 (mean 18) years and aged 20–89 (mean 56) years. We evaluated changes of estimated glomerular filtration rate (eGFR) as well as serum creatinine, urea–nitrogen, and glucose concentrations, white blood cell count, and body-mass index, and tested associations of eGFR with selected factors, using standard bivariate contrasts and regression modeling.

          Results

          Overall, 29.5% of subjects experienced at least one low value of eGFR (<60 mL/min/1.73 m 2), most after ≥15 years of treatment and age > 55; risk of ≥2 low values was 18.1%; none experienced end-stage renal failure. eGFR declined by 0.71%/year of age and 0.92%/year of treatment, both by 19% more among women than men. Mean serum creatinine increased from 0.87 to 1.17 mg/dL, BUN from 23.7 to 33.1 mg/dL, glucose from 88 to 122 mg/dL, and BMI from 25.9 to 26.6 kg/m 2. By multivariate regression, risk factors for declining eGFR ranked: longer lithium treatment, lower lithium dose, higher serum lithium concentration, older age, and medical comorbidity. Later low eGFR was also predicted by lower initial eGFR, and starting lithium at age ≥ 40 years.

          Limitations

          Control data for age-matched subjects not exposed to lithium were lacking.

          Conclusions

          Long-term lithium treatment was associated with gradual decline of renal functioning (eGFR) by about 30% more than that was associated with aging alone. Risk of subnormal eGFR was from 18.1% (≥2 low values) to 29.5% (≥1 low value), requiring about 30 years of exposure. Additional risk factors for low eGFR were higher serum lithium level, longer lithium treatment, lower initial eGFR, and medical comorbidity, as well as older age.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.

          The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines in 2012 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving renal replacement therapy. The KDIGO CKD Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team. Searches of the English-language literature were conducted through November 2012. Final modification of the guidelines was informed by the KDIGO Board of Directors and a public review process involving registered stakeholders. The full guideline included 110 recommendations. This synopsis focuses on 10 key recommendations pertinent to definition, classification, monitoring, and management of CKD in adults.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The aging kidney: physiological changes.

            Age-associated loss of kidney function has been recognized for decades. With aging, many subjects exhibit progressive decreases in glomerular filtration rate and renal blood flow, with wide variability among individuals. The fall in glomerular filtration rate is because of reductions in the glomerular capillary plasma flow rate and the glomerular capillary ultrafiltration coefficient. In addition, a primary reduction in afferent arteriolar resistance is associated with an increase in glomerular capillary hydraulic pressure. These hemodynamic changes occur in concert with structural changes, including loss of renal mass; hyalinization of afferent arterioles and in some cases, development of aglomerular arterioles; an increase in the percentage of sclerotic glomeruli; and tubulointerstitial fibrosis. Aging is associated with altered activity and responsiveness to vasoactive stimuli, such that responses to vasoconstrictor stimuli are enhanced, whereas vasodilatory responses are impaired. Changes in the activity of the renin-angiotensin and nitric oxide systems appear to be particularly important, as is the modulating effect of gender. These changes may predispose the older kidney to acute kidney injury, including normotensive ischemic nephropathy, as well as progressive chronic kidney disease. 2010 National Kidney Foundation, Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis

              Background In a previous meta-analysis of randomized controlled trials comparing lithium with placebo as a long-term treatment in bipolar disorders, we observed a clear preventative effect for manic episodes; however, the effect was equivocal for depressive episodes. Since then, the evidence base has grown further. In this update, we furthermore present the data on efficacy of lithium in comparison to alternative drug treatments. In addition, we analyze the data comparing lithium with placebo and other treatments regarding drop-outs due to reasons other than a mood episode and completion of study (no mood episode and no drop-out to reasons other than a mood episode). Methods Randomized controlled trials (RCTs) were sought comparing lithium with placebo and lithium with an alternative treatment in bipolar disorders where the stated intent of treatment was prevention of mood episodes. To this purpose, the Cochrane Central Register of Controlled Trials (CENTRAL) was searched. Reference lists of relevant papers and major textbooks of mood disorders were examined. Authors, other experts in the field, and pharmaceutical companies were contacted for knowledge of suitable trials, published or unpublished. Results For the comparison of lithium with placebo, seven trials (1,580 participants) were included. Lithium was more effective than placebo in preventing overall mood episodes (random effects RR 0.66, 95% CI 0.53 to 0.82), manic episodes (random effects RR 0.52, 95% CI 0.38 to 0.71), and, dependent on the type of analyses applied, depressive episodes (random effects RR 0.78, 95% CI 0.59 to 1.03; fixed effect RR 0.73, 95% CI 0.60 to 0.88). Lithium was inferior to placebo in leading to drop-outs for reasons other than a mood episode (random effects RR 1.33, 95% CI 1.07 to 1.65) but superior to placebo on study completion (random effects RR 1.69, 95% CI 1.12 to 2.55). For the comparison of lithium with anticonvulsants, seven trials were included (n = 1,305). In prevention of manic episodes, lithium showed superiority compared to anticonvulsants (random effects RR 0.66, 95% CI 0.44 to 1.00). However, there was no significant difference regarding prevention of overall mood episodes, depressive episodes, dropping-out to reasons other than a mood episode, or study completion. Conclusions The evidence base for lithium in the long-term treatment of bipolar disorders has strengthened. With no other drug available having such ample and consistent evidence for its efficacy lithium remains the most valuable treatment option in this indication.
                Bookmark

                Author and article information

                Contributors
                1-617-855-3203 , Ltondo@aol.com
                maria.abramowicz@gmail.com
                malda@dal.ca
                Michael.Bauer@uniklinikum-dresden.de
                bocchett@unica.it
                l.bolzani@clinicaviarnetto.ch
                Cindy.Calkin@nshealth.ca
                cchillotti@aoucagliari.it
                DAHIDALG@clinic.cat
                mirkomanchia@icloud.com
                bruno.mueller-oerlinghausen@web.de
                AMURRU@clinic.ub.es
                giulio.perugi@gmail.com
                marco87.pinna@tiscali.it
                giuseppe_40@libero.it
                daniela.reginaldi@gmail.com
                andreas.reif@kgu.de
                Philipp.Ritter@uniklinikum-dresden.de
                janusz.rybakowski@gmail.com
                david.saiger@posteo.de
                gabriele.sani@uniroma1.it
                valerioselle@hotmail.com
                thomas.stamm@charite.de
                gvazquez1900@gmail.com
                Julia.Veeh@kgu.de
                EVIETA@clinic.ub.es
                rbaldessarini@mclean.harvard.edu
                Journal
                Int J Bipolar Disord
                Int J Bipolar Disord
                International Journal of Bipolar Disorders
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                2194-7511
                1 August 2017
                1 August 2017
                2017
                : 5
                : 27
                Affiliations
                [1 ]ISNI 000000041936754X, GRID grid.38142.3c, Department of Psychiatry, , Harvard Medical School, ; Boston, MA USA
                [2 ]ISNI 0000 0000 8795 072X, GRID grid.240206.2, The International Consortium for Mood & Psychotic Disorders Research, MRC 306, , McLean Hospital, ; 115 Mill Street, Belmont, MA 02478-9106 USA
                [3 ]Lucio Bini Mood Disorders Centers, Cagliari and Rome, Italy
                [4 ]ISNI 0000 0001 2205 0971, GRID grid.22254.33, Department of Adult Psychiatry, , Poznan University of Medical Sciences, ; Poznan, Poland
                [5 ]ISNI 0000 0004 1936 8200, GRID grid.55602.34, Department of Psychiatry, , Dalhousie University, ; Halifax, NS Canada
                [6 ]Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
                [7 ]ISNI 0000 0004 1755 3242, GRID grid.7763.5, Department of Biomedical Sciences, , University of Cagliari, ; Cagliari, Italy
                [8 ]GRID grid.460105.6, Unit of Clinical Pharmacology, , Azienda Ospedaliero-Universitaria, ; Cagliari, Italy
                [9 ]Viarnetto Psychiatric Clinic, Lugano, Switzerland
                [10 ]ISNI 0000 0004 1937 0247, GRID grid.5841.8, Hospital Clinic, , University of Barcelona, IDIBAPS, CIBERSAM, ; Barcelona, Spain
                [11 ]ISNI 0000 0004 1755 3242, GRID grid.7763.5, Section of Psychiatry, Department of Medical Science and Public Health, , University of Cagliari, ; Cagliari, Italy
                [12 ]ISNI 0000 0004 1936 8200, GRID grid.55602.34, Department of Pharmacology, , Dalhousie University, ; Halifax, NS Canada
                [13 ]Freie Universität Berlin, Charité Universitäts-Medizin, Berlin, Germany
                [14 ]ISNI 0000 0004 1757 3729, GRID grid.5395.a, Department of Experimental and Clinic Medicine, Section of Psychiatry, , University of Pisa & Institute of Behavioral Science, ; Pisa, Italy
                [15 ]ISNI 0000 0004 1757 3470, GRID grid.5608.b, Department of General Psychology, Clinical Psychology, , University of Padua, ; Padua, Italy
                [16 ]ISNI 0000 0004 0578 8220, GRID grid.411088.4, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, , University Hospital Frankfurt, ; Frankfurt-am-Main, Germany
                [17 ]ISNI 0000 0001 2218 4662, GRID grid.6363.0, Department of Psychiatry, , Charité Universitäs-Medizin, ; Berlin, Germany
                [18 ]Brandenburg Medical School, Neureppin, Germany
                [19 ]GRID grid.7841.a, NeSMOS Department, , ‘Sapienza’ University and Lucio Bini Mood Disorders Center, ; Rome, Italy
                [20 ]ISNI 0000 0004 1936 8331, GRID grid.410356.5, Department of Psychiatry, , Queens University, ; Kingston, Ontario Canada
                [21 ]GRID grid.441624.1, Department of Neuroscience, , Palermo University, ; Buenos Aires, Argentina
                Article
                96
                10.1186/s40345-017-0096-2
                5537163
                28480485
                a0f51378-1a52-45c6-9d56-c27f269a9df6
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 9 December 2016
                : 18 April 2017
                Funding
                Funded by: Aretæus Foundation
                Funded by: FundRef http://dx.doi.org/10.13039/501100006546, Angelini Pharma;
                Funded by: FundRef http://dx.doi.org/10.13039/100001455, American Foundation for Suicide Prevention;
                Funded by: FundRef http://dx.doi.org/10.13039/501100002347, Bundesministerium für Bildung und Forschung;
                Funded by: German Excellence Initiative to the Graduate School of Life Sciences
                Funded by: Instituto de Salud Carlos III, Subdirección General de Evaluación y Fomento de la Investigación
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: 64410
                Award Recipient :
                Funded by: Spanish Ministry of Economy and Competitiveness
                Award ID: 00912
                Award Recipient :
                Funded by: Deutsche Forschungsgemeinschaft, European Commission
                Award ID: FP7
                Award Recipient :
                Funded by: the RTG “gk emotions”
                Award ID: 1256/2
                Award Recipient :
                Funded by: Fondo Europeo de Desarrollo Regional, Unión Europea
                Funded by: CIBERSAM and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement
                Award ID: 2014-SGR-398
                Award Recipient :
                Funded by: Bruce J. Anderson Foundation
                Funded by: McLean Private Donors Research Fund
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                blood urea nitrogen,body-mass index,creatinine,egfr,glomerular filtration rate,glucose,lithium,staging of renal function,white blood cell count

                Comments

                Comment on this article